Loading [MathJax]/jax/output/SVG/jax.js
Review

Most relevant genetic factors in ovarian cancer development

  • Ovarian cancer (OC) represents a significant challenge in the realm of gynecological cancers, characterized by poor survival rates and complex etiology. This review delves into the genetic, environmental, and hormonal factors underpinning OC development, shedding light on both well-established contributors and emerging influences. We reviewed scientific databases searching for OC genetic and epigenetic factors and included studies based on their relevancy. As a result of exploring ovarian carcinogenesis, this systematic review contains data collected from 102 works. The role of prominent genetic players, such as BRCA mutations and DNA repair mechanisms, underscores the intricate landscape of OC susceptibility. Furthermore, we explore Li-Fraumeni and Lynch syndrome, which result in a heightened predisposition to OC development. Hormonal factors such as estrogen, progesterone, and androgens are also discussed in detail. Environmental alterations, ranging from lifestyle influences to microbiome dysbiosis add layers of complexity to OC pathogenesis. Lifestyle factors such as obesity, alcohol consumption, and physical activity intersect with genetic and epigenetic pathways, shaping the risk landscape for OC. This review provides a nuanced understanding of the multifactorial nature of OC through a meticulous examination of current literature, emphasizing the need for holistic approaches to prevention, diagnosis, and treatment.

    Citation: Alicja Florczak, Aleksandra Królikowska, Mateusz Mazurek, Sławomir Woźniak, Zygmunt Domagała. Most relevant genetic factors in ovarian cancer development[J]. AIMS Molecular Science, 2025, 12(1): 1-25. doi: 10.3934/molsci.2025001

    Related Papers:

    [1] Saudia Jabeen, Bandar Bin-Mohsin, Muhammad Aslam Noor, Khalida Inayat Noor . Inertial projection methods for solving general quasi-variational inequalities. AIMS Mathematics, 2021, 6(2): 1075-1086. doi: 10.3934/math.2021064
    [2] Meiying Wang, Luoyi Shi, Cuijuan Guo . An inertial iterative method for solving split equality problem in Banach spaces. AIMS Mathematics, 2022, 7(10): 17628-17646. doi: 10.3934/math.2022971
    [3] Lu-Chuan Ceng, Shih-Hsin Chen, Yeong-Cheng Liou, Tzu-Chien Yin . Modified inertial subgradient extragradient algorithms for generalized equilibria systems with constraints of variational inequalities and fixed points. AIMS Mathematics, 2024, 9(6): 13819-13842. doi: 10.3934/math.2024672
    [4] Yali Zhao, Qixin Dong, Xiaoqing Huang . A self-adaptive viscosity-type inertial algorithm for common solutions of generalized split variational inclusion and paramonotone equilibrium problem. AIMS Mathematics, 2025, 10(2): 4504-4523. doi: 10.3934/math.2025208
    [5] Zheng Zhou, Bing Tan, Songxiao Li . Two self-adaptive inertial projection algorithms for solving split variational inclusion problems. AIMS Mathematics, 2022, 7(4): 4960-4973. doi: 10.3934/math.2022276
    [6] Pongsakorn Yotkaew, Nopparat Wairojjana, Nuttapol Pakkaranang . Accelerated non-monotonic explicit proximal-type method for solving equilibrium programming with convex constraints and its applications. AIMS Mathematics, 2021, 6(10): 10707-10727. doi: 10.3934/math.2021622
    [7] Mohammad Dilshad, Mohammad Akram, Md. Nasiruzzaman, Doaa Filali, Ahmed A. Khidir . Adaptive inertial Yosida approximation iterative algorithms for split variational inclusion and fixed point problems. AIMS Mathematics, 2023, 8(6): 12922-12942. doi: 10.3934/math.2023651
    [8] Ziqi Zhu, Kaiye Zheng, Shenghua Wang . A new double inertial subgradient extragradient method for solving a non-monotone variational inequality problem in Hilbert space. AIMS Mathematics, 2024, 9(8): 20956-20975. doi: 10.3934/math.20241020
    [9] Austine Efut Ofem, Jacob Ashiwere Abuchu, Godwin Chidi Ugwunnadi, Hossam A. Nabwey, Abubakar Adamu, Ojen Kumar Narain . Double inertial steps extragadient-type methods for solving optimal control and image restoration problems. AIMS Mathematics, 2024, 9(5): 12870-12905. doi: 10.3934/math.2024629
    [10] Cuijie Zhang, Zhaoyang Chu . New extrapolation projection contraction algorithms based on the golden ratio for pseudo-monotone variational inequalities. AIMS Mathematics, 2023, 8(10): 23291-23312. doi: 10.3934/math.20231184
  • Ovarian cancer (OC) represents a significant challenge in the realm of gynecological cancers, characterized by poor survival rates and complex etiology. This review delves into the genetic, environmental, and hormonal factors underpinning OC development, shedding light on both well-established contributors and emerging influences. We reviewed scientific databases searching for OC genetic and epigenetic factors and included studies based on their relevancy. As a result of exploring ovarian carcinogenesis, this systematic review contains data collected from 102 works. The role of prominent genetic players, such as BRCA mutations and DNA repair mechanisms, underscores the intricate landscape of OC susceptibility. Furthermore, we explore Li-Fraumeni and Lynch syndrome, which result in a heightened predisposition to OC development. Hormonal factors such as estrogen, progesterone, and androgens are also discussed in detail. Environmental alterations, ranging from lifestyle influences to microbiome dysbiosis add layers of complexity to OC pathogenesis. Lifestyle factors such as obesity, alcohol consumption, and physical activity intersect with genetic and epigenetic pathways, shaping the risk landscape for OC. This review provides a nuanced understanding of the multifactorial nature of OC through a meticulous examination of current literature, emphasizing the need for holistic approaches to prevention, diagnosis, and treatment.


    Abbreviations

    OC:

    ovarian cancer; 

    LFS:

    Li-Fraumeni syndrome; 

    PR:

    progesterone receptor; 

    PCOS:

    polycystic ovary syndrome; 

    COCPs:

    combined oral contraceptive pills; 

    DSB:

    double-strand break repair; 

    LPS:

    lipopolysaccharides

    In a real Hilbert space H, with D being a nonempty closed convex subset, where the inner product , and norm are defined, the classical variational inequality problem (VIP) is to determine a point xD such that Ax,yx0 holds for all yD, where A:HH is an operator. Then, we define as its solution set. Stampacchia [1] proposed variational inequality theory in 1964, which appeared in various models to solve a wide range of engineering, regional, physical, mathematical, and other problems. The mathematical theory of variational inequality problems was first applied to solve equilibrium problems. Within this model, the function is derived from the first-order variation of the respective potential energy. As a generalization and development of classical variational problems, the form of variational inequality has become more diverse, and many projection algorithms have been studied by scholars [2,3,4,5,6,7,8,9,10]. In [11], Hu and Wang utilized the projected neural network (PNN) to solve the VIP under the pseudo-monotonicity or pseudoconvexity assumptions. Furthermore, He et al. [12] proposed an inertial PNN method for solving the VIP, while Eshaghnezhad et al. [13] presented a novel PNN method for solving the VIP. In addition, in [14], a modified neurodynamic network (MNN) was proposed for solving the VIP, and under the assumptions of strong pseudo monotonicity and L-continuity, the fixed-time stability convergence of MNN was established.

    The most famous method for solving the VIP is called the projection gradient method (GM), which is expressed as

    xn+1=PD(xnγAxn). (1.1)

    Observably, the iterative sequence {xn} produced by this method converges towards a solution of the VIP, and PD:HD is a metric projection, with γ denoting the stepsize parameter, and A being both strongly monotone and Lipschitz continuous. The projection gradient method fails when A is weakened to a monotonic operator. On this basis, Korpelevich [15] proposed a two-step iteration called the extragradient method (EGM)

    {x0D,sn=PD(xnγAxn),xn+1=PD(xnγAsn), (1.2)

    where γ is the stepsize parameter, and A is Lipschitz continuous and monotone. However, the calculation of projection is a major challenge in each iteration process. Hence, to address this issue, Censor et al. [16] proposed the idea of the half-space and modified the algorithm to

    {sn=PD(xnγAxn),Hn={xH:xnγAxnsn,xsn0},xn+1=PHn(xnγAsn). (1.3)

    Recently, adaptive step size [17,18,19] and inertia [20,21,22,23] have been frequently used to accelerate algorithm convergence. For example, Thong and Hieu [24] presented the following algorithm:

    {hn=xn+αn(xnxn1),sn=PD(hnτnAhn),en=PHn(hnτnAsn),xn+1=βnf(en)+(1βn)en, (1.4)

    where Hn={xH:hnτnAhnsn,xsn0}, and

    τn+1={min{μhnsnAhnAsn,τn}, if AhnAsn0,τn, otherwise.

    They also combined the VIP with fixed point problems [25] (we define Δ as a common solution set). For example, Nadezhkina and Takahashi [26] proposed the following algorithm:

    {x0D,sn=PD(xnτnAxn),xn+1=(1αn)xn+αnTPD(xnτnAsn), (1.5)

    where A is Lipschitz continuous and monotone, and T:DD is nonexpansive. The sequence produced by this algorithm exhibits weak convergence toward an element in Δ. Another instance is the algorithm proposed by Thong et al. [27], which is as follows:

    {hn=xn+αn(xnxn1),sn=PD(hnτnAhn),en=PHn(hnτnAsn),xn+1=(1βn)hn+βnTen, (1.6)

    where τn is selected as the maximum τ within the set {γ,γl,γl2,...} that satisfies the condition

    τAhnAsnμhnsn.

    Based on the preceding research, we present a self-adaptive step-size and alternated inertial subgradient extragradient algorithm designed for addressing the VIP and fixed-point problems involving non-Lipschitz and pseudo-monotone operators in this paper. The article's structure is outlined as follows: Section 2 contains definitions and preliminary results essential for our approach. Section 3 establishes the convergence of the iterative sequence generated. Finally, Section 4 includes a series of numerical experiments demonstrating the practicality and effectiveness of our algorithm.

    For a sequence {xn} and x in H, strong convergence is represented as xnx, weak convergence is represented as xnx.

    Definition 2.1. [28] We define a nonlinear operator T:HH to have an empty fixed point set (Fix(T)), if the following expression holds for {qn}H:

    {qnq(IT)qn0qFix(T),

    where I denotes the identity operator. In such cases, we characterize IT as being demiclosed at zero.

    Definition 2.2. For an operator T:HH, the following definitions apply:

    (1) T is termed nonexpansive if

    Tq1Tq2q1q2q1,q2H.

    (2) T is termed quasi-nonexpansive with a non-empty fixed point set Fix(T) if

    TxηxηxH,ηFix(T).

    Definition 2.3. A sequence {qn} is said to be Fejér monotone concerning a set D if

    qn+1qqnq,qD.

    Lemma 2.1. For each ζ1,ζ2H and ϵR, we have

    ζ1+ζ222ζ1+ζ2,ζ2+ζ12; (2.1)
    ϵζ2+(1ϵ)ζ12=(1ϵ)ζ12+ϵζ22ϵ(1ϵ)ζ2ζ12. (2.2)

    Lemma 2.2. [26] Given ψH and φD, then

    (1) PDψPDφ2ψφ,PDψPDφ;

    (2) φPDψ2ψφ2ψPDψ2;

    (3) ψPDψ,PDψφ0.

    Lemma 2.3. [29] Suppose A:DH is pseudomonotone and uniformly continuous. Then, ς is a solution of Ax,xς0,xD.

    Lemma 2.4. [30] Let D be a nonempty subset of H. A sequence {xn} in H is said to weakly converge to a point in D if the following conditions are met:

    (1) For every xD, limnxnx exists;

    (2) Every sequential weak cluster point of {xn} is in D.

    This section presents an alternated inertial projection algorithm designed to address the VIP and fixed point problems associated with a quasi-nonexpansive mapping T in H. We have the following assumptions:

    Assumption 3.1.

    (a) The operator A:HH is pseudo-monotone, uniformly continuous over H, and exhibits sequential weak continuity on D;

    (b) ϖ(1μ4,1μ2), 0<κn<min{1μ2ϖ2ϖ,1ϖ1+ϖ}.

    The algorithm (Algorithm 1) is as follows:

    Algorithm 1

    Initialization: Let x0,x1H be arbitrary. Given γ>0, l(0,1), μ(0,1).
    Iterative step: Calculate xn+1 as follows:
    Step 1. Set
         hn={xn,n=even,xn+ϖ(xnxn1),n=odd.
    Step 2. Compute
         sn=PD(hnτnAhn).
    If sn=hn, stop. Otherwise compute
         en=PHn(hnτnAsn),
    where
         Hn={xH:hnτnAhnsn,xsn0},
    and τn is selected as the maximum τ from the set {γ,γl,γl2,} that satisfies
        τAsnAhn,snenμsnhnsnen.

    Step 3. Compute
        xn+1=(1κn)en+κnTen.

    Set n:=n+1 and go back to Step 1.

    To prove the algorithm, we first provide several lemmas.

    Lemma 3.1. The sequence produced by Algorithm 1, denoted as {x2n}, is bounded and limnx2nϱ exists for all ϱΔ.

    Proof. Indeed, let ϱΔ. Then, we have

    enϱ2=PHn(hnτnAsn)ϱ2hnτnAsnϱ2hnτnAsnen2=hnϱ2+τ2nAsn22τnhnϱ,Asnhnen2τ2nAsn2+2τnhnen,Asn=hnϱ2hnen2+2τnϱen,Asn=hnϱ2hnen22τnsnϱ,Asn+2τnsnen,Asn. (3.1)

    According to ϱΔ, it follows that Aϱ,sϱ for all sD, and, at the same time, because of the pseudomonotonicity of A, we establish As,sϱ0 for all sD. If we set s=sn, then Asn,snϱ0. Thus, by (3.1), we can get

    enϱ2hnϱ2hnen2+2τnsnen,Asn=hnϱ2hnsn2ensn22hnsn,snen+2τnsnen,Asn=hnϱ2hnsn2ensn2+2snhn+τnAsn,snen=hnϱ2hnsn2ensn2+2hnτnAhnsn,ensn+2τnAsnAhn,snenhnϱ2hnsn2ensn2+2μsnhnsnenhnϱ2hnsn2ensn2+μ[snhn2+ensn2]=hnϱ2(1μ)hnsn2(1μ)ensn2. (3.2)

    Subsequently, by (2.2), we obtain

    xn+1ϱ2=(1κn)en+κnTenϱ2=κn(Tenϱ)+(1κn)(enϱ)2=κnTenϱ2+(1κn)enϱ2κn(1κn)Tenen2κnenϱ2+(1κn)enϱ2κn(1κn)Tenen2=enϱ2κn(1κn)Tenen2hnϱ2(1μ)hnsn2(1μ)ensn2κn(1κn)Tenen2. (3.3)

    Meanwhile, combined with (3.3), it is evident that

    xn+1ϱ2(1κn)hnϱ2+κnenϱ2. (3.4)

    In particular,

    x2n+2ϱ2h2n+1ϱ2(1μ)h2n+1s2n+12(1μ)e2n+1s2n+12κ2n+1(1κ2n+1)Te2n+1e2n+12. (3.5)

    By (2.2), we obtain

    h2n+1ϱ2=x2n+1+ϖ(x2n+1x2n)ϱ2=(1+ϖ)x2n+1ϱ2ϖx2nϱ2+ϖ(1+ϖ)x2n+1x2n2. (3.6)

    As another special case of (3.3), we have

    x2n+1ϱ2x2nϱ2(1μ)x2ns2n2(1μ)e2ns2n2κ2n(1κ2n)Te2ne2n2x2nϱ21μ2x2ne2n2κ2n(1κ2n)Te2ne2n2, (3.7)

    and then, bringing (3.7) into (3.6), we can get

    h2n+1ϱ2=x2nϱ2(1+ϖ)(1μ)2x2ne2n2κ2n(1κ2n)(1+ϖ)Te2ne2n2+ϖ(1+ϖ)x2n+1x2n2. (3.8)

    Plugging (3.8) into (3.5) gives

    x2n+2ϱ2x2nϱ2(1+ϖ)(1μ)2x2ne2n2κ2n(1κ2n)(1+ϖ)Te2ne2n2+ϖ(1+ϖ)x2n+1x2n2(1μ)h2n+1s2n+12(1μ)e2n+1s2n+12κ2n+1(1κ2n+1)Te2n+1e2n+12, (3.9)

    where

    x2n+1x2n2=(1κ2n)e2n+κ2nTe2nx2n2=e2nx2n+κ2n(Te2ne2n)2=e2nx2n2+κ22nTe2ne2n2+2κ2ne2nx2n,Te2ne2ne2nx2n2+κ22nTe2ne2n2+κ2n(e2nx2n2+Te2ne2n2)=(1+κ2n)e2nx2n2+κ2n(κ2n+1)Te2ne2n2. (3.10)

    Thus, putting (3.10) into (3.9), we have

    x2n+2ϱ2x2nϱ2[(1+ϖ)(1μ)2ϖ(1+ϖ)(1+κ2n)]e2nx2n2[κ2n(1κ2n)(1+ϖ)ϖ(1+ϖ)κ2n(κ2n+1)]Te2ne2n2(1μ)h2n+1s2n+12(1μ)e2n+1s2n+12κ2n+1(1κ2n+1)Te2n+1e2n+12. (3.11)

    According to ϖ(1μ4,1μ2), 0<κn<min{1μ2ϖ2ϖ,1ϖ1+ϖ}, we get the sequence {x2nϱ} is decreasing, and thus limnx2nϱ exists. This implies {x2nϱ} is bounded, hence, {x2n} is bounded. For (3.7), we can get that {x2n+1ϱ} is also bounded. Therefore, {xnϱ} is bounded. Thus, {xn} is bounded.

    Lemma 3.2. Consider the sequence {x2n} produced by Algorithm 1. If the subsequence {x2nk} of {x2n} weakly converges to xH and limkx2nks2nk=0, then x.

    Proof. Because of h2n=x2n, using the definition of {s2nk} and Lemma 2.2, we get

    x2nkτ2nkAx2nks2nk,xs2nk0,xD,

    and so

    1τ2nkx2nks2nk,xs2nkAx2nk,xs2nk,xD.

    Hence,

    1τ2nkx2nks2nk,xs2nk+Ax2nk,s2nkx2nkAx2nk,xx2nk,xD. (3.12)

    Because of limkx2nks2nk=0 and taking the limit as k in (3.12), we acquire

    lim_kAx2nk,xx2nk0,xD. (3.13)

    Select a decreasing sequence {ϵk}(0,) to make limkϵk=0 hold. Then, for each ϵk, based on (3.13) we use Mk to represent the smallest positive integer satisfying

    Ax2nj,xx2nj+ϵk0,jMk. (3.14)

    Since {ϵk} is decreasing, then {Mk} is increasing. Also, for each k, Ax2Mk0, let

    v2Mk=Ax2MkAx2Mk2.

    Here, Ax2Mk,v2Mk=1 for each k. Then, by (3.14), for each k we have

    Ax2Mk,x+ϵkv2Mkx2Mk0.

    Because A is pseudo-monotonic, we get

    A(x+ϵkv2Mk),x+ϵkv2Mkx2Mk0. (3.15)

    Since x2nkx as k, and A exhibits sequential weak continuity on H, it follows that the sequence {Ax2nk} weakly converges to Ax. Then, based on the weakly sequential continuity of the norm, we obtain

    0<Axlim_kAx2nk.

    Since {xMk}{xnk} and limkϵk=0, we have

    0¯limkϵkv2Mk=¯limk(ϵkAx2nk)¯limkϵklim_kAx2nk=0Ax=0,

    which means limkϵkv2Mk=0. Finally, we let k in (3.15) and get

    Ax,xx0.

    This implies x.

    Lemma 3.3. Considering {x2n} as the sequence produced by Algorithm 1, since {x2n} is a bounded sequence, there exists a subsequence {x2nk} of {x2n} and xH such that x2nkx. Hence, xΔ.

    Proof. From (3.11) and the convergence of {x2nϱ}, we can deduce that

    e2n+1s2n+10,x2nx2n+10, (3.16)
    h2n+1s2n+10,Te2ne2n0, (3.17)
    Te2n+1e2n+10,asn+.

    By the definition of {x2n+1}, we have

    x2ne2n=x2nx2n+1+κ2n(Te2ne2n)x2nx2n+1+κ2nTe2ne2n,

    then

    x2ne2n0, (3.18)

    and by (3.18) and x2nkx, we can get

    e2nkx. (3.19)

    Since T is demiclosed at zero, Definition 2.1, (3.17), and (3.19) imply

    xFix(T). (3.20)

    From (3.2), we deduce

    e2nϱ2x2nϱ2(1μ)x2ns2n2(1μ)e2ns2n2.

    This implies that

    (1μ)x2ns2n2x2nϱ2e2nϱ2. (3.21)

    Based on the convergence of {x2nϱ2}, we can assume that

    x2nϱ2l. (3.22)

    At the same time, according to (3.16), it can be obtained that

    x2n+1ϱ2l. (3.23)

    It follows from (3.4) that

    x2n+1ϱ2(1κ2n)x2nϱ2+κ2ne2nϱ2.

    Then,

    e2nϱ2x2n+1ϱ2x2nϱ2κ2n+x2nϱ2. (3.24)

    It implies from (3.22)–(3.24) that

    limne2nϱ2limnx2nϱ2=l. (3.25)

    By (3.2), we get

    limne2nϱ2limnx2nϱ2=l. (3.26)

    Combining (3.25) and (3.26), we get

    limne2nϱ2=l. (3.27)

    Combining with (3.21), (3.22), and (3.27), we have

    limnx2ns2n2=0.

    Therefore, it implies from Lemma 3.2 that

    x. (3.28)

    Combining (3.20) and (3.28), we can derive

    xΔ.

    Theorem 3.2. {xn}, a sequence produced by Algorithm 1, weakly converges to a point within Δ.

    Proof. Let xH such that x2nkx. Then, by Lemma 3.3, it implies

    xΔ.

    Combining limnx2nϱ2 exists for all ϱΔ, and by Lemma 2.4, we get that {x2n} converges weakly to an element within Δ. Now, suppose {x2n} converges weakly to ξΔ. For all gH, it follows that

    limnx2nξ,g=0.

    Furthermore, by (3.16), for all gH,

    |x2n+1ξ,g|=|x2n+1x2n+x2nξ,g||x2n+1x2n,g|+|x2nξ,g|x2n+1x2ng+|x2nξ,g|0,asn.

    Therefore, {x2n+1} weakly converges to ξΔ. Hence, {xn} weakly converges to ξΔ

    This section will showcase three numerical experiments aiming to compare Algorithm 1 against scheme (1.6) and Algorithm 6.1 in [31], and Algorithm 3.1 in [32]. All codes were written in MATLAB R2018b and performed on a desktop PC with Intel(R) Core(TM) i5-8250U CPU @ 1.60GHz 1.80 GHz, RAM 8.00 GB.

    Example 4.1. Assume that H=R3 and D:={xR3:Φxϕ}, where Φ represents a 3×3 matrix and ϕ is a nonnegative vector. For A(x):=Qx+q, with Q=BBT+E+F, where B is a 3×3 matrix, E is a 3×3 skew-symmetric matrix, F is a 3×3 diagonal matrix with nonnegative diagonal entries, and q is a vector in R3. Notably, A is both monotone and Lipschitz continuous with constant L=Q. Define T(x)=x,xR3.

    Under the assumption q=0, the solution set Δ={0}, which means that x=0. Now, the error at the n-th step iteration is measured using xnx. In both Algorithm 1 and scheme (1.6), we let μ=0.5, γ=0.5, l=0.5; in Algorithm 1, we let ϖ=0.2, κn=0.2; in scheme (1.6), we let αn=0.25, βn=0.5; in Algorithm 6.1 in [31], we let τ=0.01, αn=0.25; in Algorithm 3.1 in [32], we let αn=1n+1, βn=n2n+1, f(x)=0.5x, τ1=1, μ=0.2, θ=0.3, ϵn=100(n+1)2. The outcomes of this numerical experiment are presented in Table 1 and Figure 1.

    Table 1.  Numerical results for Example 4.1.
    Iter. Time [sec]
    Algorithm 1 297 1.7283
    scheme (1.6) 482 3.0215
    Algorithm 6.1 in [31] 1311 8.5415
    Algorithm 3.1 in [32] 477 2.3758

     | Show Table
    DownLoad: CSV
    Figure 1.  Comparison of Algorithm 1 and scheme (1.6), Algorithm 6.1 in [31], and Algorithm 3.1 in [32] for Example 4.1.

    From Table 1, we can see that the algorithm in this article has the least number of iterations and the shortest required time. Therefore, this indicates that Algorithm 1 is feasible. According to the situation shown in Figure 1, we can see that Algorithm 1 is more efficient than the other two algorithms.

    Example 4.2. Consider H=R and the feasible set D=[2,5]. Let A:HH be defined as

    At:=t+sin(t),

    and T:HH be defined as

    Tt:=t2sin(t).

    It is evident that A is Lipschitz continuous and monotone, while T is a quasi-nonexpansive mapping. Consequently, it is straightforward to observe that Δ={0}.

    In Algorithm 1 and scheme (1.6), we let γ=0.5, l=0.5, μ=0.9; in Algorithm 1, we let κn=23, ϖ=0.03; in scheme (1.6), we let αn=0.25, βn=0.5; in Algorithm 6.1 in [31], we let τ=0.4, αn=0.5, in Algorithm 3.1 in [32], we let αn=1n+1, βn=n2n+1, f(x)=0.5x, τ1=1, μ=0.2, θ=0.3, ϵn=100(n+1)2. The results of the numerical experiment are shown in Table 2 and Figure 2.

    Table 2.  Numerical results for Example 4.2.
    Iter. Time [sec]
    Algorithm 1 20 0.3542
    scheme (1.6) 26 0.5168
    Algorithm 6.1 in [31] 41 0.4293
    Algorithm 3.1 in [32] 26 0.3574

     | Show Table
    DownLoad: CSV
    Figure 2.  Comparison of Algorithm 1 and scheme (1.6), Algorithm 6.1 in [31], and Algorithm 3.1 in [32] for Example 4.2.

    Table 2 and Figure 2 illustrate that Algorithm 1 has a faster convergence speed.

    Example 4.3. Consider H=L2([0,1]) with the inner product

    m,n:=10m(p)n(p)dpm,nH,

    and the induced norm

    m:=(10|m(p)|2dp)12mH.

    The operator A:HH is defined as

    (Am)(p)=max{0,m(p)},p[0,1]mH.

    The set D:={mH:m1} represents the unit ball. Specifically, the projection operator PD(m) is defined as

    PD(m)={mmL2,mL2>1,m,mL21.

    Let T:L2([0,1])L2([0,1]) be defined by

    (Tm)(p)=m(p)2.

    Therefore, we can get that Δ={0}.

    In Algorithm 1 and scheme (1.6), we let γ=0.5, l=0.5, μ=0.5; in Algorithm 1, we let κn=0.2, ϖ=0.2; in scheme (1.6), we let αn=0.25, βn=0.3; in Algorithm 6.1 in [31], we let τ=0.9, αn=0.6. The results of the numerical experiment are shown in Figure 3.

    Figure 3.  Comparison of Algorithm 1 and scheme (1.6), and Algorithm 6.1 in [31] for Example 4.3.

    Figure 3 shows the behaviors of En=xnx generated by all the algorithms, commencing from the initial point x0(p)=p2. The presented results also indicate that our algorithm is superior to other algorithms.

    This paper introduces a novel approach for tackling variational inequality problems and fixed point problems. Algorithm 1 extends the operator A to pseudo-monotone, uniformly continuous, and incorporates a new self-adaptive step size, and adds an alternated inertial method based on scheme (1.6). The efficiency of our algorithm is validated through the results obtained from three distinct numerical experiments.

    The authors declare they have not used Artificial Intelligence (AI) tools in the creation of this article.

    This work was supported by the National Natural Science Foundation of China (Grant No. 12171435).

    The authors declare that they have no competing interests.


    Acknowledgments



    The authors would like to thank Małgorzata Smazek Ryndak for the language correction and Piotr Baron for helping create the tables and figures.

    Conflict of interest



    The authors declare no conflict of interest.

    [1] Gupta S, Rajappa S, Advani S, et al. (2021) Prevalence of BRCA1 and BRCA2 mutations among patients with ovarian, primary peritoneal, and fallopian tube cancer in India: A multicenter cross-sectional study. JCO Glob Oncol 7: 849-861. https://doi.org/10.1200/GO.21.00051
    [2] Ovarian Cancer Research AllianceOvarian cancer (2024). Available from: https://ocrahope.org/get-the-facts/statistics/
    [3] Cabasag CJ, Fagan PJ, Ferlay J, et al. (2022) Ovarian cancer today and tomorrow: A global assessment by world region and Human Development Index using GLOBOCAN 2020. Int J Cancer 151: 1535-1541. https://doi.org/10.1002/ijc.34002
    [4] Ovarian Cancer StatisticsKey Statistics for Ovarian Cancer (2024). Available from: https://www.cancer.org/cancer/types/ovarian-cancer/about/key-statistics.html
    [5] Toss A, Tomasello C, Razzaboni E, et al. (2015) Hereditary ovarian cancer: Not only BRCA 1 and 2 Genes. Biomed Res Int 2015: 341723. https://doi.org/10.1155/2015/341723
    [6] Avramenko AS, Flanagan JM (2023) An epigenetic hypothesis for ovarian cancer prevention by oral contraceptive pill use. Clin Epigenet 15: 165. https://doi.org/10.1186/S13148-023-01584-9
    [7] Domański J, Domagala Z, Simmons JE, et al. (2023) Terra Incognita in anatomical museology–A literature review from the perspective of evidence-based care. Ann Anat 245: 152013. https://doi.org/10.1016/J.AANAT.2022.152013
    [8] Mateusz M, Oliwier P, Mateusz D, et al. (2024) Decoding the mysteries of the obturator nerve. J Anat Soc India 73: 64-69. https://doi.org/10.4103/JASI.JASI_122_23
    [9] Domagała D, Data K, Szylle H, et al. (2024) Cellular, molecular and clinical aspects of aortic aneurysm—vascular physiology and pathophysiology. Cells 13: 274. https://doi.org/10.3390/CELLS13030274
    [10] Xu K, Yang S, Zhao Y (2017) Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis. Oncotarget 8: 285-302. https://doi.org/10.18632/ONCOTARGET.12306
    [11] Casaubon JT, Kashyap S, Regan JP BRCA1 and BRCA2 mutations (2023). Available from: https://www.ncbi.nlm.nih.gov/books/NBK470239/
    [12] Varol U, Kucukzeybek Y, Alacacioglu A, et al. (2018) BRCA genes: BRCA 1 and BRCA 2. J BUON 23: 862-866.
    [13] Venkitaraman AR Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108: 171-182. https://doi.org/10.1016/S0092-8674(02)00615-3
    [14] Vergote I, González-Martínet A, Ray-Coquardal I, et al. (2022) European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. Ann Oncol 33: 276-287. https://doi.org/10.1016/j.annonc.2021.11.013
    [15] Tutt ANJ, Lord CJ, Mccabe N, et al. (2005) Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol 70: 139-148. https://doi.org/10.1101/SQB.2005.70.012
    [16] Doig KD, Fellowes AP, Fox SB (2023) Homologous Recombination Repair Deficiency: An Overview for Pathologists. Modern Pathol 36: 100049. https://doi.org/10.1016/j.modpat.2022.100049
    [17] McCarthy N (2005) A positive defect. Nat Rev Cancer 5: 333. https://doi.org/10.1038/nrc1618
    [18] Villani A, Frebourg T, Malkin D (2021) Li-fraumeni syndrome. The hereditary basis of childhood cancer . Cham: Springer 1-21. https://doi.org/10.1007/978-3-030-74448-9_1
    [19] Guha T, Malkin D (2017) Inherited TP53 mutations and the Li-fraumeni syndrome. Cold Spring Harb Perspect Med 7: a026187. https://doi.org/10.1101/CSHPERSPECT.A026187
    [20] Sorrell AD, Espenschied CR, Culver JO, et al. (2013) Tumor protein p53 (TP53) testing and Li-Fraumeni Syndrome. Mol Diagn Ther 17: 31-47. https://doi.org/10.1007/S40291-013-0020-0
    [21] Kumamoto T, Yamazaki F, Nakano Y, et al. (2021) Medical guidelines for Li–Fraumeni syndrome 2019, version 1.1. Int J Clin Oncol 26: 2161-2178. https://doi.org/10.1007/S10147-021-02011-W
    [22] Genes by Name. Available from: https://www.facingourrisk.org/info/hereditary-cancer-and-genetic-testing/hereditary-cancer-genes-and-risk/genes-by-name
    [23] Ryan NA, McMahon RF, Ramchander NC, et al. (2021) Lynch syndrome for the gynaecologist. TOG 23: 9-20. https://doi.org/10.1111/TOG.12706
    [24] Underkofler KA, Ring KL (2023) Updates in gynecologic care for individuals with lynch syndrome. Front Oncol 13: 1127683. https://doi.org/10.3389/FONC.2023.1127683
    [25] Bansidhar BJ, Silinsky J (2012) History and Pathogenesis of Lynch Syndrome. Clin Colon Rectal Surg 25: 63-66. https://doi.org/10.1055/S-0032-1313776
    [26] McRonald FE, Pethick J, Santaniello F, et al. (2024) Identification of people with Lynch syndrome from those presenting with colorectal cancer in England: baseline analysis of the diagnostic pathway. Eur J Hum Genet 32: 529-538. https://doi.org/10.1038/s41431-024-01550-w
    [27] Hampel H, De La Chapelle A (2011) The search for unaffected individuals with Lynch syndrome: Do the ends justify the means?. Cancer Prev Res (Phila) 4: 1-5. https://doi.org/10.1158/1940-6207.CAPR-10-0345
    [28] Grindedal EM, Renkonen-Sinisalo L, Vasen H, et al. (2010) Survival in women with MMR mutations and ovarian cancer: A multicentre study in Lynch syndrome kindreds. J Med Genet 47: 99-102. https://doi.org/10.1136/JMG.2009.068130
    [29] Broaddus RR, Lynch HT, Chen L, et al. (2006) Pathologic features of endometrial carcinoma associated with HNPCC: A comparison with sporadic endometrial carcinoma. Cancer 106: 87-94. https://doi.org/10.1002/CNCR.21560
    [30] Christianson CA, Powell KP, Hahn SE, et al. (2012) The use of a family history risk assessment tool within a community health care system: views of primary care providers. J Genet Couns 21: 652-661. https://doi.org/10.1007/S10897-011-9479-1
    [31] Crosbie EJ, Ryan NA, Arends MJ, et al. (2019) The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome. Genet Med 21: 2390-2400. https://doi.org/10.1038/S41436-019-0489-Y
    [32] Weiss JM, Gupta S, Burke C, et al. (2021) NCCN guidelines® insights: Genetic/familial high-risk assessment: Colorectal, version 1.2021. J Natl Compr Canc Netw 19: 1122-1132. https://doi.org/10.1164/jnccn.2021.0048
    [33] Burn J, Sheth H, Elliott F, et al. (2020) Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet 395: 1855-1863.
    [34] Burton AM, Peterson SK, Marani SK, et al. (2010) Health and lifestyle behaviors among persons at risk for Lynch syndrome. Cancer Causes Control 21: 513-521. https://doi.org/10.1007/S10552-009-9482-0
    [35] Kurose K, Zhou XP, Araki T, et al. (2001) Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary Epithelial ovarian carcinomas. Am J Pathol 158: 2097-2106. https://doi.org/10.1016/S0002-9440(10)64681-0
    [36] Li X, Miao C, Wang L, et al. (2023) Estrogen promotes Epithelial ovarian cancer cells proliferation via down-regulating expression and activating phosphorylation of PTEN. Arch Biochem Biophys 743: 109662. https://doi.org/10.1016/J.ABB.2023.109662
    [37] Syed V, Ho SM (2003) Progesterone-induced apoptosis in immortalized normal and malignant human ovarian surface epithelial cells involves enhanced expression of FasL. Oncogene 2003 22: 6883-6890. https://doi.org/10.1038/sj.onc.1206828
    [38] Syed V, Ulinski G, Mok SC, et al. (2002) Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells. JNCI: J Natl Cancer I 94: 617-629. https://doi.org/10.1093/JNCI/94.8.617
    [39] Sarwar S, Alamro A, Huq F, et al. (2022) Insights into the role of epigenetic factors determining the estrogen response in estrogen-positive ovarian cancer and prospects of combining epi-drugs with endocrine therapy. Front Genet 13: 812077. https://doi.org/10.3389/FGENE.2022.812077
    [40] Zhou B, Sun Q, Cong R, et al. (2008) Hormone replacement therapy and ovarian cancer risk: A meta-analysis. Gynecol Oncol 108: 641-651. https://doi.org/10.1016/j.ygyno.2007.12.003
    [41] Mungenast F, Thalhammer T (2014) Estrogen biosynthesis and action in ovarian cancer. Front Endocrinol 5: 192. https://doi.org/10.3389/FENDO.2014.00192
    [42] Choi JH, Wong AST, Huang HF, et al. (2007) Gonadotropins and ovarian cancer. Endocr Rev 28: 440-461. https://doi.org/10.1210/ER.2006-0036
    [43] Yang H, Dai H, Li L, et al. (2019) Age at menarche and epithelial ovarian cancer risk: A meta-analysis and Mendelian randomization study. Cancer Med 8: 4012-4022. https://doi.org/10.1002/CAM4.2315
    [44] Nowak-Markwitz E, Spaczyński M (2012) Ovarian cancer–modern approach to its origin and histogenesis. Ginekol Pol 83: 454-457.
    [45] Kujawa KA, Lisowska KM (2015) Rak jajnika–od biologii do kliniki. Postepy Hig Med Dosw 69: 1275-1290.
    [46] Ochman K Utrata heterozygotyczności loci sprzężonych z genami BRCA1 i BRCA2 w rakach jajnika (2006).
    [47] Moorman PG, Havrilesky LJ, Gierisch JM, et al. (2013) Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: A systematic review and meta-analysis. J Clin Oncol 31: 4188-4198. https://doi.org/10.1200/JCO.2013.48.9021
    [48] Merritt MA, Riboli E, Murphy N, et al. (2015) Reproductive factors and risk of mortality in the European prospective investigation into cancer and nutrition; a cohort study. BMC Med 13: 252. https://doi.org/10.1186/s12916-015-0484-3
    [49] Syed V, Ulinski G, Mok SC, et al. (2001) Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 61: 6768-6776.
    [50] Ye Q, Cai W, Zheng Y, et al. (2014) ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer. Oncogene 33: 1828-1839. https://doi.org/10.1038/ONC.2013.122
    [51] Modugno F (2004) Ovarian cancer and polymorphisms in the androgen and progesterone receptor genes: A HuGE review. Am J Epidemiol 159: 319-335. https://doi.org/10.1093/AJE/KWH046
    [52] Pearce CL, Wu AH, Gayther SA, et al. (2008) Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the ovarian cancer association consortium pooled analysis. Br J Cancer 98: 282-288. https://doi.org/10.1038/SJ.BJC.6604170
    [53] Terry KL, De Vivo I, Titus-Ernstoff L, et al. (2005) Genetic variation in the progesterone receptor gene and ovarian cancer risk. Am J Epidemiol 161: 442-451. https://doi.org/10.1093/AJE/KWI064
    [54] Leite DB, Junqueira MG, de Carvalho CV, et al. (2008) Progesterone receptor (PROGINS) polymorphism and the risk of ovarian cancer. Steroids 73: 676-680. https://doi.org/10.1016/J.STEROIDS.2008.02.005
    [55] Runnebaum IB, Wang-Gohrke S, Vesprini D, et al. (2001) Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. Pharmacogenetics 11: 635-638. https://doi.org/10.1097/00008571-200110000-00010
    [56] Throwba P.K H, Unnikrishnan L, Pangath M, et al. (2022) The epigenetic correlation among ovarian cancer, endometriosis and PCOS: A review. Crit Rev Oncol Hematol 180: 103852. https://doi.org/10.1016/J.CRITREVONC.2022.103852
    [57] Reid BM, Permuth JB, Sellers TA (2017) Epidemiology of ovarian cancer: A review. Cancer Biol Med 14: 9-32. https://doi.org/10.20892/J.ISSN.2095-3941.2016.0084
    [58] Troisi R, Bjørge T, Grotmol T, et al. (2018) The role of pregnancy, perinatal factors, and hormones in maternal cancer risk: A review of the evidence. J Intern Med 283: 430-445. https://doi.org/10.1111/JOIM.12747
    [59] Tsilidis KK, Allen NE, Key TJ, et al. (2011) Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 105: 1436-1442. https://doi.org/10.1038/bjc.2011.371
    [60] Toufakis V, Katuwal S, Pukkala E, et al. (2021) Impact of parity on the incidence of ovarian cancer subtypes: a population-based case-control study. Acta Oncol 60: 850-855. https://doi.org/10.1080/0284186X.2021.1919754
    [61] Ramírez-de-Arellano A, Villegas-Pineda JC, Hernández-Silva CD, et al. (2021) The relevant participation of prolactin in the genesis and progression of gynecological cancers. Front Endocrinol 12: 747810. https://doi.org/10.3389/FENDO.2021.747810
    [62] Lurie G, Wilkens LR, Thompson PJ, et al. (2008) Combined oral contraceptive use and epithelial ovarian cancer risk: Time-related effects. Epidemiology 19: 237-243. https://doi.org/10.1097/EDE.0B013E31816334C5
    [63] Samkari AA, Alsulami M, Bataweel L, et al. (2022) Body microbiota and its relationship with benign and malignant breast tumors: A systematic review. Cureus 14: e25473. https://doi.org/10.7759/CUREUS.25473
    [64] Reitano E, de'Angelis N, Gavriilidis P, et al. (2021) Oral bacterial microbiota in digestive cancer patients: A systematic review. Microorganisms 9: 2585. https://doi.org/10.3390/microorganisms9122585
    [65] Yu X, Shi Y, Yuan R, et al. (2023) Microbial dysbiosis in oral squamous cell carcinoma: A systematic review and meta-analysis. Heliyon 9: e13198. https://doi.org/10.1016/J.HELIYON.2023.E13198
    [66] Mun LS, Lum SW, Sze GKY, et al. (2021) Association of microbiome with oral squamous cell carcinoma: A systematic review of the metagenomic studies. Int J Environ Res Public Health 18: 7224. https://doi.org/10.3390/IJERPH18147224
    [67] Banerjee S, Tian T, Wei Z, et al. (2017) The ovarian cancer oncobiome. Oncotarget 8: 36225-36245. https://doi.org/10.18632/ONCOTARGET.16717
    [68] Hu X., et al. (2023) Gut microbiota dysbiosis promotes the development of epithelial ovarian cancer via regulating Hedgehog signaling pathway. Gut Microbes 15: 2221093. https://doi.org/10.1080/19490976.2023.2221093
    [69] Siddiqui R, Makhlouf Z, Alharbi AM, et al. (2022) The gut microbiome and female health. Biology 11: 1683. https://doi.org/10.3390/BIOLOGY11111683
    [70] Sipos A, Ujlaki G, Mikó E, et al. (2021) The role of the microbiome in ovarian cancer: mechanistic insights into oncobiosis and to bacterial metabolite signaling. Mol Med 27: 33. https://doi.org/10.1186/S10020-021-00295-2
    [71] Nené NR, Reisel D, Leimbach A, et al. (2019) Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: A case-control study. Lancet Oncol 20: 1171-1182. https://doi.org/10.1016/S1470-2045(19)30340-7
    [72] Łaniewski P, Ilhan ZE, Herbst-Kralovetz MM (2020) The microbiome and gynaecological cancer development, prevention and therapy. Nat Rev Urol 17: 232-250. https://doi.org/10.1038/S41585-020-0286-Z
    [73] Lu YC, Yeh WC, Ohashi PS (2008) LPS/TLR4 signal transduction pathway. Cytokine 42: 145-151. https://doi.org/10.1016/J.CYTO.2008.01.006
    [74] Bertani B, Ruiz N (2018) Function and biogenesis of lipopolysaccharides. EcoSal Plus 8: 1-19. https://doi.org/10.1128/ECOSALPLUS.ESP-0001-2018
    [75] Cazzaniga M, Cardinali M, Di Pierro F, et al. (2022) Ovarian microbiota, ovarian cancer and the underestimated role of HPV. Int J Mol Sci 23: 16019. https://doi.org/10.3390/IJMS232416019
    [76] Gulve N, Rudel T (2019) Chlamydia trachomatis and human herpesvirus 6 infections in ovarian cancer—Casual or causal?. PLoS Pathog 15: e1008055. https://doi.org/10.1371/JOURNAL.PPAT.1008055
    [77] Pathak S, Wilczyński JR, Paradowska E (2020) Factors in oncogenesis: Viral infections in ovarian cancer. Cancers 12: 561. https://doi.org/10.3390/CANCERS12030561
    [78] Gonzalez SL, Stremlau M, He X, et al. (2001) Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7. J Virol 75: 7583-7591. https://doi.org/10.1128/JVI.75.16.7583-7591.2001
    [79] Liu X, Clements A, Zhao K, et al. (2006) Structure of the human papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor. J Biol Chem 281: 578-586. https://doi.org/10.1074/JBC.M508455200
    [80] Paradowska E, Jabłońska A, Studzińska M, et al. (2019) Detection and genotyping of CMV and HPV in tumors and fallopian tubes from epithelial ovarian cancer patients. Sci Rep 9: 19935. https://doi.org/10.1038/s41598-019-56448-1
    [81] Malisic E, Jankovic R, Jakovljevic K (2012) Detection and genotyping of human papillomaviruses and their role in the development of ovarian carcinomas. Arch Gynecol Obstet 286: 723-728. https://doi.org/10.1007/S00404-012-2367-6
    [82] Svahn MF, Faber MT, Christensen J, et al. (2014) Prevalence of human papillomavirus in epithelial ovarian cancer tissue. A meta-analysis of observational studies. Acta Obstet Gyn Scan 93: 6-19. https://doi.org/10.1111/AOGS.12254
    [83] Olsen CM, Green AC, Whiteman DC, et al. (2007) Obesity and the risk of epithelial ovarian cancer: A systematic review and meta-analysis. Eur J Cancer 43: 690-709. https://doi.org/10.1016/J.EJCA.2006.11.010
    [84] Urbute A, Frederiksen K, Kjaer SK (2022) Early adulthood overweight and obesity and risk of premenopausal ovarian cancer, and premenopausal breast cancer including receptor status: Prospective cohort study of nearly 500,000 Danish women. Ann Epidemiol 70: 61-67. https://doi.org/10.1016/J.ANNEPIDEM.2022.03.013
    [85] Liu ZY, Gao X, Zhu S, et al. (2019) Dietary inflammatory index and risk of gynecological cancers: A systematic review and meta-analysis of observational studies. J Gynecol Oncol 30: e32. https://doi.org/10.3802/JGO.2019.30.E23
    [86] Ding N, Zhan J, Shi Y, et al. (2022) Obesity in children and adolescents and the risk of ovarian cancer: A systematic review and dose–response meta-analysis. PLoS One 17: e0278050. https://doi.org/10.1371/JOURNAL.PONE.0278050
    [87] Friedenreich CM, Ryder-Burbidge C, McNeil J (2021) Physical activity, obesity and sedentary behavior in cancer etiology: Epidemiologic evidence and biologic mechanisms. Mol Oncol 15: 790-800. https://doi.org/10.1002/1878-0261.12772
    [88] Baczewska M, Bojczuk K, Kołakowski A, et al. (2021) Obesity and energy substrate transporters in ovarian cancer—Review. Molecules 26: 1659. https://doi.org/10.3390/MOLECULES26061659
    [89] Khanlarkhani N, Azizi E, Amidi F, et al. (2022) Metabolic risk factors of ovarian cancer: A review. JBRA Assist Reprod 26: 335-347. https://doi.org/10.5935/1518-0557.20210067
    [90] Kolomeyevskaya N, Eng KH, Khan ANH, et al. (2015) Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer. Gynecol Oncol 138: 352-357. https://doi.org/10.1016/J.YGYNO.2015.05.009
    [91] Ray A, Fornsaglio J, Dogan S, et al. (2024) Gynaecological cancers and leptin: A focus on the endometrium and ovary. Facts Views Vis Obgyn 10: 5-18.
    [92] Larsson SC, Spyrou N, Mantzoros CS (2022) Body fatness associations with cancer: Evidence from recent epidemiological studies and future directions. Metabolism 137: 155326. https://doi.org/10.1016/J.METABOL.2022.155326
    [93] Wu D, Yang H, Winham SJ, et al. (2018) Mediation analysis of alcohol consumption, DNA methylation, and epithelial ovarian cancer. J Hum Genet 63: 339-348. https://doi.org/10.1038/S10038-017-0385-8
    [94] Cvetkovic D (2003) Early events in ovarian oncogenesis. Reprod Biol Endocrinol 1: 68. https://doi.org/10.1186/1477-7827-1-68
    [95] Liu S, Feng S, Du F, et al. (2023) Association of smoking, alcohol, and coffee consumption with the risk of ovarian cancer and prognosis: a mendelian randomization study. BMC Cancer 23: 256. https://doi.org/10.1186/S12885-023-10737-1
    [96] Cook LS, Leung AC, Swenerton K, et al. (2016) Adult lifetime alcohol consumption and invasive epithelial ovarian cancer risk in a population-based case-control study. Gynecol Oncol 140: 277-284. https://doi.org/10.1016/j.ygyno.2015.12.005
    [97] Tanha K, Mottaghi A, Nojomi M, et al. (2021) Investigation on factors associated with ovarian cancer: An umbrella review of systematic review and meta-analyses. J Ovarian Res 14: 153. https://doi.org/10.1186/S13048-021-00911-Z
    [98] Pelucchi C, Bosetti C, Galeone C, et al. (2015) Dietary acrylamide and cancer risk: An updated meta-analysis. Int J Cancer 136: 2912-2922. https://doi.org/10.1002/IJC.29339
    [99] Kotsopoulos J, Vitonis AF, Terry KL, et al. (2009) Coffee intake, variants in genes involved in caffeine metabolism, and the risk of epithelial ovarian cancer. Cancer Causes Control 20: 335-344. https://doi.org/10.1007/S10552-008-9247-1
    [100] Pan JY, Haile RW, Templeton A, et al. (2018) Worldwide practice patterns in Lynch syndrome diagnosis and management, based on data from the international mismatch repair consortium. Clin Gastroenterol H 16: 1901-1910. https://doi.org/10.1016/j.cgh.2018.04.025
    [101] Harris HR, Terry KL (2016) Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: A systematic review. Fertil Res Pract 2: 14. https://doi.org/10.1186/S40738-016-0029-2
    [102] Rosenthal AN, Fraser LS, Philpott S, et al. (2017) Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the United Kingdom familial ovarian cancer screening study. J Clin Oncol 35: 1411-1420. https://doi.org/10.1200/JCO.2016.69.9330
  • This article has been cited by:

    1. Qian Yan, Libo An, Gang Cai, Qiao-Li Dong, Strong convergence of inertial extragradient methods for solving pseudomonotone variational inequality problems, 2025, 10075704, 108938, 10.1016/j.cnsns.2025.108938
  • Reader Comments
  • © 2025 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(1342) PDF downloads(95) Cited by(0)

Figures and Tables

Figures(8)  /  Tables(3)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog